Willing to participate with the ability to consent and sign an Informed Consent Form (ICF).
Treatment decision according to approved local label. Retrospective inclusion of patients who had initiated tolebrutinib up to a maximum of 4 weeks prior to signing the ICF is allowed.
You may not be if
Participation in tolebrutinib long-term safety (LTS) study or any prior tolebrutinib study; experience with any other Bruton's Tyrosine Kinase (BTK) inhibitors.
Current or planned/pending participation in a clinical study.
Inability to comply with the study protocol
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
